First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The trial will be conducted across eight sites in Maharashtra
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
